186 related articles for article (PubMed ID: 18474571)
1. Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice.
Song CH; Furuoka H; Kim CL; Ogino M; Suzuki A; Hasebe R; Horiuchi M
J Gen Virol; 2008 Jun; 89(Pt 6):1533-1544. PubMed ID: 18474571
[TBL] [Abstract][Full Text] [Related]
2. Epitope scanning reveals gain and loss of strain specific antibody binding epitopes associated with the conversion of normal cellular prion to scrapie prion.
Pan T; Li R; Kang SC; Wong BS; Wisniewski T; Sy MS
J Neurochem; 2004 Sep; 90(5):1205-17. PubMed ID: 15312175
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of peripheral administration of an anti-prion protein antibody on mice infected with prions.
Ohsawa N; Song CH; Suzuki A; Furuoka H; Hasebe R; Horiuchi M
Microbiol Immunol; 2013 Apr; 57(4):288-97. PubMed ID: 23586633
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies inhibit prion replication and delay the development of prion disease.
White AR; Enever P; Tayebi M; Mushens R; Linehan J; Brandner S; Anstee D; Collinge J; Hawke S
Nature; 2003 Mar; 422(6927):80-3. PubMed ID: 12621436
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of prion propagation in scrapie-infected mouse neuroblastoma cell lines using mouse monoclonal antibodies against prion protein.
Miyamoto K; Nakamura N; Aosasa M; Nishida N; Yokoyama T; Horiuchi H; Furusawa S; Matsuda H
Biochem Biophys Res Commun; 2005 Sep; 335(1):197-204. PubMed ID: 16061207
[TBL] [Abstract][Full Text] [Related]
6. Flow Cytometric Detection of PrP
Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046463
[TBL] [Abstract][Full Text] [Related]
7. Microglia Are Critical in Host Defense against Prion Disease.
Carroll JA; Race B; Williams K; Striebel J; Chesebro B
J Virol; 2018 Aug; 92(15):. PubMed ID: 29769333
[TBL] [Abstract][Full Text] [Related]
8. Biological effects and use of PrPSc- and PrP-specific antibodies generated by immunization with purified full-length native mouse prions.
Petsch B; Müller-Schiffmann A; Lehle A; Zirdum E; Prikulis I; Kuhn F; Raeber AJ; Ironside JW; Korth C; Stitz L
J Virol; 2011 May; 85(9):4538-46. PubMed ID: 21345946
[TBL] [Abstract][Full Text] [Related]
9. Generation of antibodies against prion protein by scrapie-infected cell immunization of PrP(0/0) mice.
Nakamura N; Miyamoto K; Shimokawa M; Nishida N; Mohri S; Kitamoto T; Horiuchi H; Furusawa S; Matsuda H
Hybrid Hybridomics; 2003 Aug; 22(4):263-6. PubMed ID: 14511572
[TBL] [Abstract][Full Text] [Related]
10. Anti-prion antibodies for prophylaxis following prion exposure in mice.
Sigurdsson EM; Sy MS; Li R; Scholtzova H; Kascsak RJ; Kascsak R; Carp R; Meeker HC; Frangione B; Wisniewski T
Neurosci Lett; 2003 Jan; 336(3):185-7. PubMed ID: 12505623
[TBL] [Abstract][Full Text] [Related]
11. Infection route-independent accumulation of splenic abnormal prion protein.
Inoue Y; Yamakawa Y; Sakudo A; Kinumi T; Nakamura Y; Matsumoto Y; Saeki K; Kamiyama T; Onodera T; Nishijima M
Jpn J Infect Dis; 2005 Apr; 58(2):78-82. PubMed ID: 15858284
[TBL] [Abstract][Full Text] [Related]
12. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis.
Mallucci G; Dickinson A; Linehan J; Klöhn PC; Brandner S; Collinge J
Science; 2003 Oct; 302(5646):871-4. PubMed ID: 14593181
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells.
Yamasaki T; Suzuki A; Hasebe R; Horiuchi M
PLoS One; 2014; 9(9):e106516. PubMed ID: 25181483
[TBL] [Abstract][Full Text] [Related]
14. Anti-prion Protein Antibody 6D11 Restores Cellular Proteostasis of Prion Protein Through Disrupting Recycling Propagation of PrP
Pankiewicz JE; Sanchez S; Kirshenbaum K; Kascsak RB; Kascsak RJ; Sadowski MJ
Mol Neurobiol; 2019 Mar; 56(3):2073-2091. PubMed ID: 29987703
[TBL] [Abstract][Full Text] [Related]
15. Tracing conformational transition of abnormal prion proteins during interspecies transmission by using novel antibodies.
Ushiki-Kaku Y; Endo R; Iwamaru Y; Shimizu Y; Imamura M; Masujin K; Yamamoto T; Hattori S; Itohara S; Irie S; Yokoyama T
J Biol Chem; 2010 Apr; 285(16):11931-6. PubMed ID: 20177064
[TBL] [Abstract][Full Text] [Related]
16. Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation.
Kim CL; Karino A; Ishiguro N; Shinagawa M; Sato M; Horiuchi M
J Gen Virol; 2004 Nov; 85(Pt 11):3473-3482. PubMed ID: 15483265
[TBL] [Abstract][Full Text] [Related]
17. Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo.
Sadowski MJ; Pankiewicz J; Prelli F; Scholtzova H; Spinner DS; Kascsak RB; Kascsak RJ; Wisniewski T
Neurobiol Dis; 2009 May; 34(2):267-78. PubMed ID: 19385058
[TBL] [Abstract][Full Text] [Related]
18. Comparative profiling of highly enriched 22L and Chandler mouse scrapie prion protein preparations.
Moore RA; Timmes A; Wilmarth PA; Priola SA
Proteomics; 2010 Aug; 10(15):2858-69. PubMed ID: 20518029
[TBL] [Abstract][Full Text] [Related]
19. Development of antibody fragments for immunotherapy of prion diseases.
Campana V; Zentilin L; Mirabile I; Kranjc A; Casanova P; Giacca M; Prusiner SB; Legname G; Zurzolo C
Biochem J; 2009 Mar; 418(3):507-15. PubMed ID: 19000036
[TBL] [Abstract][Full Text] [Related]
20. Genetic and infectious prion diseases.
Prusiner SB
Arch Neurol; 1993 Nov; 50(11):1129-53. PubMed ID: 8105771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
